Cycloset is a drug owned by Veroscience Llc. It is protected by 21 US drug patents filed from 2013 to 2021. Out of these, 12 drug patents are active and 9 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 30, 2032. Details of Cycloset's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5866584 | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov, 2012
(11 years ago) |
Expired
|
| US5756513 | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov, 2012
(11 years ago) |
Expired
|
| US5468755 | Therapeutic process for the treatment of the pathologies of Type II diabetes |
Nov, 2012
(11 years ago) |
Expired
|
| US5679685 | Accelerated release composition containing bromocriptine |
Oct, 2014
(9 years ago) |
Expired
|
| US5716957 | Method for modifying and resetting the bloodstream prolactin levels of a human subject |
Feb, 2015
(9 years ago) |
Expired
|
| US8137992 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(1 year, 3 days ago) |
Expired
|
| US7888310 | Methods of identifying responders to dopamine agonist therapy |
Jul, 2023
(1 year, 3 days ago) |
Expired
|
| US8137993 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(1 year, 3 days ago) |
Expired
|
| US8137994 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(1 year, 3 days ago) |
Expired
|
| US8877708 | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) | Active |
| US9895422 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) | Active |
| US9352025 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) | Active |
| US10688155 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) | Active |
| US9192576 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
| US10688094 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
| US9993474 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
| US8431155 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
| US9522117 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
| US11000522 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
| US9700555 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
| US8613947 | Bromocriptine formulations |
Apr, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cycloset's patents.
Latest Legal Activities on Cycloset's Patents
Given below is the list of recent legal activities going on the following patents of Cycloset.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688155 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688094 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8137993 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8137994 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8137992 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 May, 2023 | US9192576 |
| 11.5 yr surcharge- late pmt w/in 6 mo, Large Entity | 10 Oct, 2022 | US7888310 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Oct, 2022 | US7888310 |
| Maintenance Fee Reminder Mailed | 03 Oct, 2022 | US7888310 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 13 May, 2022 | US8877708 |
FDA has granted several exclusivities to Cycloset. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cycloset, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cycloset.
Exclusivity Information
Cycloset holds 1 exclusivities. All of its exclusivities have expired in 2012. Details of Cycloset's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2012 |
US patents provide insights into the exclusivity only within the United States, but Cycloset is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cycloset's family patents as well as insights into ongoing legal events on those patents.
Cycloset's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Cycloset's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 30, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cycloset Generics:
Bromocriptine Mesylate is the generic name for the brand Cycloset. 6 different companies have already filed for the generic of Cycloset, with Aurobindo Pharma Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cycloset's generic
About Cycloset
Cycloset is a drug owned by Veroscience Llc. It is used for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. Cycloset uses Bromocriptine Mesylate as an active ingredient. Cycloset was launched by Veroscience in 2009.
Market Authorisation Date:
Cycloset was approved by FDA for market use on 05 May, 2009.
Active Ingredient:
Cycloset uses Bromocriptine Mesylate as the active ingredient. Check out other Drugs and Companies using Bromocriptine Mesylate ingredient
Treatment:
Cycloset is used for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.
Dosage:
Cycloset is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.8MG BASE | TABLET | Prescription | ORAL |